Explore 3 Stock Ideas & Industry Insights Download Free Report

News

ECD Automotive (NASDAQ:ECDA) Forms U.S. Alliance for New Luxury Defender and Grenadier Builds

ECD Automotive Design, Inc. (NASDAQ:ECDA), announced a U.S. distribution alliance with Chelsea Truck Company (“CTC”), a subsidiary of Kahn Design. The partnership will develop a new series of Land Rover Defender L663 and INEOS Grenadier builds under the joint brandECD × CTC.

Team Kalkine | 10 November 2025

WISeSat.Space Holdings to Go Public via WISeKey (NASDAQ:WKEY) and Columbus (NASDAQ:COLA) Deal

WISeKey International Holding AG (NASDAQ:WKEY)and Columbus Acquisition Corp. (NASDAQ:COLA), a publicly traded SPAC, have signed a definitive Business Combination Agreement. The agreement merges Columbus with WISeKey’s wholly owned subsidiary, WISeSat.Space Corp., resulting in a publicly listed entity on Nasdaq under the name WISeSat.Space Holdings …

Team Kalkine | 10 November 2025

Rumble (NASDAQ:RUM) Secures USD 150Mn GPU Commitment from Tether for AI

Rumble Inc. (NASDAQ:RUM)disclosed a significant GPU services commitment from Tether, the largest digital asset company and creator of the widely adopted dollar stablecoin. Tether’s initial pledge covers up to USD 150 mn of GPU services over a two-year period, dependent on the closing of …

Team Kalkine | 10 November 2025

Jabil (NYSE:JBL) and Inno to Co-Invest in New Battery Enclosure Manufacturing Site in Rayong

Jabil Inc. (NYSE:JBL), a global engineering, supply chain, and manufacturing solutions company, has announced an expanded collaboration with Inno, a metal parts manufacturer and subsidiary of Shanghai Xinpeng Industry Co. (XP). The two companies will jointly invest in a 15,000-square-meter, two-building facility in Rayong, …

Team Kalkine | 10 November 2025

Innate Pharma (Nasdaq: IPHA) Receives FDA Clearance to Initiate Phase 3 TELLOMAK 3 Trial

Innate Pharma SA (NASDAQ:IPHA) announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL). The FDA had no further comments, allowing the trial to proceed.

Team Kalkine | 10 November 2025

Viomi (NASDAQ: VIOT) Delivers Record-High Revenue on Home Water Solutions Focus

Viomi Technology Co., Ltd. (NASDAQ:VIOT), a technology company specializing in home water solutions in China, announced its unaudited financial results for the six months ended June 30, 2025.

Team Kalkine | 10 November 2025

Kyivstar (NASDAQ:KYIV) Q3 Revenue Hits USD 297Mn with Digital Revenue Surging 531%

Kyivstar Group Ltd. (NASDAQ:KYIV), Ukraine’s leading digital operator, released selected unaudited financial and operational results for the third quarter ending September 30, 2025. Total revenue climbed 20.9% YoY to UAH 12.3 bn (USD 297 mn), reflecting the Group’s pricing policies and growth in consumer …

Team Kalkine | 10 November 2025

e.l.f. Beauty (NYSE:ELF) Expands Reach with ULTA Beauty Launch in Mexico

e.l.f. Beauty (NYSE:ELF)has officially launched its products at ULTA Beauty locations throughout Mexico, following the brand’s initial market introduction in 2024. The launch represents a continuation of the partnership between e.l.f. and ULTA Beauty, offering customers nationwide access to e.l.f. Cosmetics and e.l.f. SKIN …

Team Kalkine | 10 November 2025

Organon (NYSE:OGN) Reports Pediatric Trial Data Showing VTAMA® Improvements in Atopic Dermatitis

Organon (NYSE:OGN)reported findings from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 trials at the 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting. The analysis assessed VTAMA® (tapinarof) cream, 1%, in children aged 2-17 with …

Team Kalkine | 10 November 2025

Merck (NYSE:MRK) Enlicitide Shows 59% LDL-C Reduction in Phase 3 HeFH Trial

Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, released results from the pivotal Phase 3 CORALreef HeFH trial at the American Heart Association Scientific Sessions 2025. The study assessed enlicitide decanoate, an investigational once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, …

Team Kalkine | 10 November 2025
Support

Hi! How can we help you today?

Loading…